Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tegoprubart - Eledon Pharmaceuticals

Next Previous
X
Search
Drug Profile

Tegoprubart - Eledon Pharmaceuticals

Alternative Names: Anti-CD40 ligand monoclonal antibody - ALS Therapy Development Institute/Eledon Pharmaceuticals; Anti-CD40 ligand monoclonal antibody - Eledon Pharmaceuticals; Anti-CD40L - ALS Therapy Development Institute; AT-1501

Latest Information Update: 06 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALS Therapy Development Institute
  • Developer Eledon Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Allotransplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Renal transplant rejection
  • Phase I/II Islet cell transplant rejection
  • Phase I Xenotransplant rejection
  • Preclinical Liver transplant rejection
  • No development reported Autoimmune disorders
  • Discontinued Allotransplant rejection; IgA nephropathy

Most Recent Events

  • 05 Sep 2024 Eledon Pharmaceuticals completes enrolment in phase-I/II clinical trials in Renal transplant rejection (Prevention) in US, Australia, France, Germany, Spain, Brazil and Canada (IV) (NCT05983770)
  • 07 May 2024 Adverse events and efficacy data from a phase Ib Renal transplant rejection released by Eledon Pharmaceuticals
  • 04 Apr 2024 Discontinued - Phase-II for IgA nephropathy (In the elderly, In adults) in Philippines, Poland, Sri Lanka, United Kingdom, Croatia, Thailand (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top